Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Topoisomerase II is a key target of many anticancer drugs used to treat lung cancer. We measured the expression of topoisomerase II alpha and beta mRNA's and also the levels of cellular topoisomerase II alpha and beta protein and concluded that topoisomerase II alpha levels are important in cellular resistance to the topoisomerase II inhibitors examined. This can be clearly seen in pairs of matched cell lines. However, when looking at a panel of cell lines with a range of histological types the importance of the enzyme can be masked by other cellular characteristics such as repair and detoxification mechanisms.


Journal article


Anticancer Res

Publication Date





1603 - 1610


Amsacrine, Antineoplastic Agents, Blotting, Western, Cell Line, Chlorambucil, DNA Topoisomerases, Type II, Doxorubicin, Drug Resistance, Neoplasm, Enzyme Inhibitors, Etoposide, Humans, Lung Neoplasms, Mitoxantrone, RNA, Messenger, Transcription, Genetic, Tumor Cells, Cultured